Weekly Recap | Abbvie +2.66%, closing in on record highs
I'm LongbridgeAI, I can summarize articles.AbbVie (ABBV) added 2.66% this week to close at $263.96, outperforming the S&P 500 by roughly 2.74 percentage points. The stock opened Monday at $261.67, dipped to $257.795 intraday, then climbed steadily through the week to a Friday high of $266.34 before settling at $263.96. The close sits less than 1.5% below the 60-day range high of $267.47.
The Week
AbbVie (ABBV) added 2.66% this week to close at $263.96, outperforming the S&P 500 by roughly 2.74 percentage points. The stock opened Monday at $261.67, dipped to $257.795 intraday, then climbed steadily through the week to a Friday high of $266.34 before settling at $263.96. The close sits less than 1.5% below the 60-day range high of $267.47.
Key Events
The week skewed positive on the news front. AbbVie appeared on biotech watch lists on Monday, then on Tuesday was named official pharmaceutical sponsor of the PGA Tour and the 2026 Presidents Cup, launching a brain-health campaign. Several reports highlighted progress across its immunology, neuroscience, and oncology pipeline, particularly the Apogee Therapeutic collaboration and the post-HUMIRA growth roadmap. Thursday brought a note suggesting the stock could be about 4% undervalued after Phase 3 trial wins, and Friday’s real-world data showed Vraylar improving symptoms in major depressive disorder and bipolar I depression.
Analyst Ratings
Of the 30 brokerages covering the stock, 16 rate it buy, 8 rate it overweight, 5 rate it hold, and 1 rates it underweight, with no sell ratings. The consensus rating is buy, and the consensus target of $278.60714 stands about 5.55% above the current price of $263.96. Targets range from a low of $200 to a high of $328, reflecting a wide spread. Among 501 biotech names, AbbVie ranks 4th on overall analyst rating.
The Week Ahead
Macro data dominate next week. US Richmond Fed composite index arrives Tuesday, EIA weekly crude and Cushing inventories land Wednesday, and Thursday brings initial jobless claims, the current account balance, new home sales and natural gas storage. No company earnings are on the calendar yet, but follow-up interpretation of the recent Phase 3 and Vraylar real-world data is worth watching.
In Short
AbbVie edged higher this week, with most brokers rating it buy or overweight and a consensus target about 5.55% above spot. Yet the wide target range points to divided views on where the stock goes from here. On the latest trading day, large-lot order flow was a net buyer while small-lot flow was a net seller, suggesting different positioning between institutions and retail. Watch how Phase 3 follow-through and US macro data shape sentiment in the biotech complex.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.